Office safer than the operating theatre for intravitreal injections

Article

The incidence of endophthalmitis following injections of anti-VEGF drugs is lower when the injections are given in an office setting than the rates reported from clinical trials, which require a more extensive pre-injection regimen.

The incidence of endophthalmitis following injections of anti-VEGF drugs is lower when the injections are given in an office setting than the rates reported from clinical trials, which require a more extensive pre-injection regimen, according to the results of a study published online ahead of print by the American Journal of Ophthalmology.

Suman Pilli from the Vitreous Retina Macula Consultants of New York and colleagues from centres across the US and UK, carried out a retrospective interventional case series to determine the incidence of endophthalmitis following intravitreal injections of anti-VEGF agents. A total of 10,254 intravitreal injections were performed between 5th January 2005 and 18th October 2007 (406 pegaptanib, 3,501 bevacizumab and 6,347 ranibizumab). The injections were performed as an office-based procedure, using povidone-iodine as part of the pre-injection preparation. Pre-injection antibiotics, eye drape or surgical attire were not used.

Overall, there were just three cases of suspected endophthalmitis, one case following bevacizumab injection and two cases following ranibizumab injection. There were no cases of culture-proven endophthalmitis and all three patients regained their pre-injection visual acuity.

Compared to the stricter procedures used in clinical trials, office-based injection procedures actually result in fewer cases of endophthalmitis, conclude the authors of this study.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.